検索
TG Therapeutics Inc
TGTXウォッチリストに追加
55.900USD
+0.180+0.32%
取引時間 （ET）15分遅れの株価
8.56B時価総額
17.46直近12ヶ月PER
詳細情報 TG Therapeutics Inc 企業名
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
TG Therapeutics Incの企業情報
企業コードTGTX
会社名TG Therapeutics Inc
上場日Dec 14, 1995
最高経営責任者「CEO」Weiss (Michael S)
従業員数338
証券種類Ordinary Share
決算期末Dec 14
本社所在地3020 Carrington Mill Blvd., Suite 475
都市MORRISVILLE
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号27560-5435
電話番号18775758489
ウェブサイトhttps://www.tgtherapeutics.com/
企業コードTGTX
上場日Dec 14, 1995
最高経営責任者「CEO」Weiss (Michael S)
TG Therapeutics Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
9.78M
--
Mr. Sean A. Power
Mr. Sean A. Power
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
690.61K
--
Mr. Kenneth (Ken) Hoberman
Mr. Kenneth (Ken) Hoberman
Independent Director
Independent Director
279.65K
--
Dr. Yann Echelard
Dr. Yann Echelard
Independent Director
Independent Director
223.82K
--
Mr. Daniel Hume, J.D.
Mr. Daniel Hume, J.D.
Independent Director
Independent Director
192.75K
--
Mr. Laurence Neil (Larry) Charney, CPA
Mr. Laurence Neil (Larry) Charney, CPA
Lead Independent Director
Lead Independent Director
179.69K
--
Dr. Sagar Lonial
Dr. Sagar Lonial
Independent Director
Independent Director
94.06K
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
9.78M
--
Mr. Sean A. Power
Mr. Sean A. Power
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
690.61K
--
Mr. Kenneth (Ken) Hoberman
Mr. Kenneth (Ken) Hoberman
Independent Director
Independent Director
279.65K
--
Dr. Yann Echelard
Dr. Yann Echelard
Independent Director
Independent Director
223.82K
--
Mr. Daniel Hume, J.D.
Mr. Daniel Hume, J.D.
Independent Director
Independent Director
192.75K
--
Mr. Laurence Neil (Larry) Charney, CPA
Mr. Laurence Neil (Larry) Charney, CPA
Lead Independent Director
Lead Independent Director
179.69K
--
よくある質問
TG Therapeutics Incの上位5名の株主は誰ですか？
TG Therapeutics Incの上位5名の株主は以下のとおりです。Mr. Michael S. Weiss, J.D.
TG Therapeutics Inc（TGTX）の株式を保有している機関の数はいくつですか？
2026Q1時点で、TG Therapeutics Incの株式を保有している機関は760社あり、保有株式の総市場価値は約122.50Mで、全体の80.02%を占めています。2025Q4と比較して、機関の持ち株は4398281.00増加しています。
TG Therapeutics Incの最大の収益源は何ですか？
2026Q1において、Total product revenue, net部門がTG Therapeutics Incにとって最大の収益を生み出しており、その金額は606.93Mで、全収益の98.48%を占めています。
